LLC1 / LLC1-luc Orthotopic Mouse Model Service for Lung Cancer

The LLC1 / LLC1-luc orthotopic mouse model for lung cancer grows a KRAS-mutant Lewis lung carcinoma within the pulmonary environment of immunocompetent C57BL/6 mice, pairing an immune-intact tumor microenvironment with non-invasive bioluminescence readouts. Operating strictly in preclinical oncology, Alfa Cytology delivers this syngeneic platform as a complete service: authenticated LLC1 / LLC1-luc cell supply, route-matched orthotopic inoculation (tail vein, intrathoracic, or intranasal), scheduled in vivo imaging, and full histopathological endpoint analysis.

Overview of LLC1 / LLC1-luc Orthotopic Mouse Model for Lung Cancer

LLC1 (LL/2) descends from the Lewis lung carcinoma, one of the oldest transplantable mouse tumors in existence, which arose spontaneously in a C57BL/6 mouse in 1951 and was passed through generations of syngeneic hosts ever since. The widely used ATCC version, catalogued as CRL-1642, was established by Bertram and Janik in 1980 and is now understood—through whole-exome sequencing—to originate from a male C57BL/6L donor and to carry an unusually high mutation burden accumulated during decades of laboratory propagation. Genetically, LLC1 mirrors major features of human non-small cell lung cancer: an activating KRAS G12C mutation, Trp53 and Cdkn2a alterations, and prominent Myc expression. Its long passage history in immune-competent animals has also selected a highly immune-evasive phenotype with a strongly immunosuppressive tumor microenvironment, making LLC1 the standard syngeneic lung cancer model—and a key counterpoint to immunotherapy-sensitive lines such as CT26—for preclinical immunology research.

Fig 1. Blood-derived CTCs from orthotopic LLC-luc tumors formed distal metastases detectable by in vivo and ex vivo bioluminescence in liver, adrenal gland, bone and brain after intracardiac injection, and metastatic distribution of the LLC-based syngeneic model mirrored human lung cancer patterns better than the A549 xenograft. (Picabea, Beñat, et al., 2025)

For orthotopic lung cancer work, luciferase-tagged LLC1 (LLC1-luc, including the commercially available CRL-1642-LUC2 reporter) can be introduced through several route-matched strategies, each answering a different question. Tail-vein injection of 5 × 10⁵ to 1 × 10⁶ cells is the classic approach, though it can seed multiple sites with incomplete penetrance; direct intrathoracic injection of ~5 × 10⁵ cells in a 25 µl volume into the left lung produces confirmed thoracic signals within a week; intranasal instillation (two 50 µl doses of 0.5 × 10⁶ cells) delivers cells non-invasively to the lower respiratory tract with documented reproducibility; and subcutaneous dosing of 5 × 10⁵ cells yields palpable tumors by day five for pharmacology screens. Whole-animal bioluminescence after D-luciferin administration quantifies tumor burden longitudinally, works even in black-furred C57BL/6 animals, and supports two- to four-week therapeutic windows with survival, lung nodule scoring, and H&E confirmation at endpoint. Figure 1 outlines this orthotopic system.

Cell Line Information: LLC1 / LLC1-luc

LLC1 is among the most deeply studied syngeneic lung cancer lines, and its luciferase-tagged derivatives have made it the default choice for imaging-based orthotopic lung research. The defining characteristics are summarized below.

Our Services

An LLC1 / LLC1-luc engagement with Alfa Cytology is executed as one continuous program: route selection matched to the scientific question, rigorous mycoplasma control for immunology-grade work, pre-agreed IVIS imaging cadence, and a terminal package combining lung nodule counts, ex vivo organ imaging, and flow-cytometric profiling of the tumor microenvironment.

Workflow of LLC1 / LLC1-luc Orthotopic Mouse Model Construction

Establishing an LLC1 or LLC1-luc orthotopic lung tumor begins with a route decision—each inoculation strategy carries distinct biological implications—followed by disciplined cell handling, imaging-driven monitoring, and structured endpoint analysis. The workflow below describes the standard execution of this platform.

1. Cell Bank Verification and Expansion: LLC1 or LLC1-luc stocks are authenticated (ATCC-supplied reporter lines verified for growth, mycoplasma, and species identity) and expanded in DMEM-based medium, with strict contamination control given the line’s immunology applications.
2. Luciferase Calibration (LLC1-luc Only): In vitro signal per cell is verified so that in vivo photon flux can be converted into relative tumor burden across cohorts.
3. Host Preparation and Route Selection: C57BL/6 mice are acclimatized and randomized by body weight; the study design selects the inoculation route—tail vein for systemic seeding, intrathoracic injection for a single defined lung nodule, or intranasal instillation for a non-invasive, microenvironment-focused format.
4. Orthotopic Inoculation: Cells are delivered per the chosen route: tail vein (5 × 10⁵–1 × 10⁶ cells in 200 µl), left-lung intrathoracic injection (5 × 10⁵ cells in 25 µl under anesthesia with surgical staple closure), or two intranasal doses of 0.5 × 10⁶ cells in 50 µl each with dropwise inhalation.
5. Engraftment Confirmation: A first IVIS session a few days after inoculation confirms cell take and establishes baseline radiance for each animal.
6. Longitudinal Monitoring and Treatment: Whole-animal bioluminescence is captured on a scheduled basis after D-luciferin (100–150 mg/kg i.p. or 3 mg s.c.), with body weight recorded in parallel; test agents or immunotherapy combinations are dosed per the study design.
7. Scheduled Endpoint Harvesting: Animals are typically euthanized three to four weeks after inoculation (or at humane endpoints); lungs are resected, the five lobes are inspected for macroscopic nodules, and major organs are collected for ex vivo imaging.
8. Histopathology and Immune Profiling: Lung sections are H&E stained for tumor burden quantification (e.g., QuPath image analysis), and tumor-digest flow cytometry profiles the microenvironment (CD8⁺ T cells, Tregs, macrophages, PD-L1) to complete the dataset.

Fig 2. LLC1 / LLC1-luc orthotopic mouse model construction workflow.

Case Study-LLC1 / LLC1-luc Orthotopic Mouse Model Development

Alfa Cytology has run preclinical programs on the LLC1 / LLC1-luc orthotopic platform for clients pursuing microenvironment-reprogramming combinations, KRAS-pathway targeting, and antivascular strategies, delivering longitudinal bioluminescence growth curves, lung nodule burden maps, and flow-cytometry-supported microenvironment analyses. Because each engagement is configured around the client’s own therapeutic hypothesis, detailed study outlines and representative datasets are available upon request.

Why Choose Alfa Cytology?

LLC1 / LLC1-luc orthotopic work rewards route literacy and immunology discipline: the model only performs when the inoculation strategy matches the question and contamination never enters the picture. Alfa Cytology’s process controls keep these variables locked down across every cohort.

• Authenticated LLC1 / LLC1-luc banks with rigorous mycoplasma control suitable for immunology-grade studies.
• Route expertise spanning tail-vein, intrathoracic, and intranasal inoculation matched to the scientific question.
• Calibrated in-house IVIS imaging that quantifies tumor burden longitudinally in fur-bearing C57BL/6 mice.
• Immunocompetent syngeneic hosts preserving the full tumor microenvironment for combination-immunotherapy research.
• Endpoint packages combining lung nodule counts, ex vivo organ imaging, and microenvironment flow cytometry.
• A dedicated project team owning the study from route design through final data delivery.

Contact Us

From microenvironment-reprogramming combinations to KRAS-directed strategies, Alfa Cytology can configure the LLC1 / LLC1-luc orthotopic lung cancer study around your specific preclinical question. Contact us today to discuss route selection, study design, and imaging cadence, or reach out to our team for a customized quotation.

For research use only. Not intended for any clinical use.